PTC Therapeutics
A science-led, patient-centered biopharmaceutical company focused on discovering, developing and commercializing medicine for patients with rare disease.
Market cap
$4.0b
Enterprise value
$2.3b
Share price
$48.84 PTCT
Recent deals
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $1.0b | Post IPO Equity | |
| Total Funding | 000k | ||
Credit Suisse(exited)
CDIB Capital Group(exited)
Delphi(exited)
HealthCap(exited)
Manulife Financial(exited)
Novo Holdings(exited)
Bay City Capital(exited)
CDI Bioscience(exited)
Delphi Ventures(exited)
New Medical Technologies(exited)
HBM BioVentures(exited)
Celgene(exited)
The Column Group(exited)
Brookside Capital(exited)
Adage Capital(exited)
Jennison Associates(exited)
Longwood Fund(exited)
Cercano Management(exited)
Amgen Ventures(exited)
Credit Suisse First Boston(exited)
HBM Healthcare Investments(exited)
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 41 % | 30 % | 34 % | (14 %) | 102 % | (47 %) | 21 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (70 %) | (53 %) | (11 %) | 4 % | 54 % | 3 % | 25 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (97 %) | (80 %) | (67 %) | (45 %) | 30 % | (26 %) | (3 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 100 % | 93 % | 71 % | 66 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by PTC Therapeutics
EditACQUISITION by PTC Therapeutics Jul 2018
ACQUISITION by PTC Therapeutics May 2020